SIEGALL CLAY B Insider Trading Activity

Average Profitability
74.21%
Insider Buys Quantity
7
Insider Buys Sum
$5.51M
Insider Sells Quantity
2
Insider Sells Sum
$2.14M

Insider Activity of SIEGALL CLAY B

According to the SEC Form 4 filings, SIEGALL CLAY B, being in a position of

  1. President and CEO at Immunome, Inc.,
    оver the last 12 months, has bought 83968 shares for $1.75M, and sold 0 shares,
    over all time since 2023-10-02, has bought 740272 shares for $7.26M, and sold 0 shares.

Biography of SIEGALL CLAY B

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$1,999,6605100
Sells
$000

Comparison of Insiders on Amount of Buys and Sells

2026-06-09PurchaseShattuck Labs, Inc.
STTK
director
62,500
0.1222%
$4.00$250,000+52.34%
2026-03-27PurchaseImmunome, Inc.
IMNM
President and CEO
25,450
0.0291%
$19.67$500,602+14.51%
2025-12-30PurchaseImmunome, Inc.
IMNM
President and CEO
4,729
0.0051%
$21.15$100,018+4.79%
2025-12-19PurchaseImmunome, Inc.
IMNM
President and CEO
7,278
0.0076%
$20.48$149,053+3.36%
2025-12-18PurchaseImmunome, Inc.
IMNM
President and CEO
46,511
0.0547%
$21.50$999,987+11.08%
2025-03-26PurchaseImmunome, Inc.
IMNM
President and CEO
137,100
0.1621%
$7.29$999,459+59.94%
2025-01-31PurchaseImmunome, Inc.
IMNM
President and CEO
150,000
0.1772%
$7.75$1.16M-9.79%
2024-11-22PurchaseImmunome, Inc.
IMNM
President and CEO
33,943
0.0543%
$9.78$331,918+0.81%
2024-11-21PurchaseImmunome, Inc.
IMNM
President and CEO
66,057
0.1059%
$9.54$630,263+5.1%
2024-05-21PurchaseImmunome, Inc.
IMNM
President and CEO
20,434
0.0344%
$13.78$281,548-12.16%
2024-05-20PurchaseImmunome, Inc.
IMNM
President and CEO
79,566
0.1337%
$13.91$1.11M-12.93%
2023-10-02PurchaseImmunome, Inc.
IMNM
President and CEO
169,204
0.9994%
$5.91$999,996+74.21%
2020-08-10SaleUltragenyx Pharmaceutical Inc.
RARE
director
1,596
0.0026%
$85.01$135,676+25.25%
2020-08-07SaleUltragenyx Pharmaceutical Inc.
RARE
director
23,404
0.0389%
$85.55$2M+25.78%
Total: 14
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.